nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

15.11.2017 | editorial

ASCO 2017—making a difference in cancer care with you

verfasst von: Gabriel Rinnerthaler, M.D.

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Excerpt

For the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) 5817 abstracts had been submitted and 2463 were finally selected for presentation. To spread this enormous gain of knowledge, new ways of information exchange become increasingly important. With webcasts and news tickers, presentations at international congresses can be followed at home. Furthermore, continuing medical education events and published reviews illuminate the presented data from different perspectives. In this special edition, Austrian specialists summarize the important and most clinically relevant data from this year’s ASCO. …

Vorheriger Artikel Revival of anti-angiogenic therapies in cancer—news on an old therapeutic concept

Nächster Artikel Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update

Hida T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390(10089):29–39.CrossRefPubMed

Gadgeel Shirish M, et al. Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts). J Clin Oncol. 2017;35(15_suppl):8504–8504.

Hellmann Matthew D, et al. Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032. J Clin Oncol. 2017;35(15_suppl):8503–8503.

von Minckwitz G, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(2):122–31.CrossRef

Robson M, et al. Olaparib for metastatic breast cancer in patients with a Germline BRCA mutation. N Engl J Med. 2017;377(6):523–33.CrossRefPubMed

Rummel Mathias J, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: nine-year updated results from the StiL NHL1 study. J Clin Oncol. 2017;35(15_suppl):7501–7501.

Flinn Ian, et al. First-line treatment of iNHL or MCL patients with BR or R‑CHOP/R-CVP: Results of the BRIGHT 5‑year follow-up study. J Clin Oncol. 2017;35(15_suppl):7500–7500.

Pfreundschuh Michael, et al. Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL〉60 study of the DSHNHL. J Clin Oncol. 2017;35(15_suppl):7506–7506.

Raje Noopur S, et al. Impact of denosumab (DMB) compared with zoledronic acid (ZA) on renal function in the treatment of myeloma bone disease. J Clin Oncol. 2017;35(15_suppl):8005–8005.

10.

Chawla Sant P, et al. Phase III study of aldoxorubicin vs investigators’ choice as treatment for relapsed/refractory soft tissue sarcomas. J Clin Oncol. 2017;35(15_suppl):11000–11000.

11.

Burgess Melissa A, et al. Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): final results of SARC028 and biomarker analyses. J Clin Oncol. 2017;35(15_suppl):11008–11008.

12.

D’Angelo Sandra P, et al. A multi-center phase II study of nivolumab +/− ipilimumab for patients with metastatic sarcoma (Alliance A091401). J Clin Oncol. 2017;35(15_suppl):11007–11007.

13.

Noronha Vanita, et al. Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer. J Clin Oncol. 2017;35(15_suppl):6007–6007.

14.

Omid H, et al. Epacadostat plus pembrolizumab in patients with SCCHN: preliminary phase I/II results from ECHO-202/KEYNOTE-037. J Clin Oncol. 2017;35(15_suppl):6010–6010.

15.

Harter Philipp, et al. LION: Lymphadenectomy in ovarian neoplasms—a prospective randomized AGO study group led gynecologic cancer intergroup trial. J Clin Oncol. 2017;35(15_suppl):5500–5500.

16.

Ledermann Jonathan A, et al. Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer. J Clin Oncol. 2017;35(15_suppl):5506–5506.

17.

Mansoor Raza M, et al. Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. J Clin Oncol. 2017;35(15_suppl):5517–5517.

18.

Hollebecque Antoine, et al. An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (checkmate 358): efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers. J Clin Oncol. 2017;35(15_suppl):5504–5504.

19.

Shi Qian, et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): the IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. J Clin Oncol. 2017;35(18_suppl):LBA1–LBA1.CrossRef

20.

Al-Batran Salah-Eddin, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. J Clin Oncol. 2017;35(15_suppl):4004–4004.

21.

Primrose John N, et al. Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study. J Clin Oncol. 2017;35(15_suppl):4006–4006.

Titel: ASCO 2017—making a difference in cancer care with you
verfasst von: Gabriel Rinnerthaler, M.D.
Publikationsdatum: 15.11.2017
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2017
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-017-0364-y

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Aggressive lymphoma 2016: revision of the WHO classification

The first meeting of the Austrian Expert Panel for Molecular Cancer Profiling

ASCO update – what is new in the systemic treatment of advanced soft tissue sarcomas?

Antiangiogenic therapy in breast cancer

ASCO update on lymphoma

Antiangiogenic therapies in urogenital malignancies